Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE vs ACTIVELLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal renal tubule, reducing plasma glucose independent of insulin secretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, increasing insulin release and decreasing glucagon secretion.
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
Oral: 1 tablet (dapagliflozin 5 mg / saxagliptin 5 mg) once daily, taken with or without food, in combination with metformin or other glucose-lowering agents.
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
Dapagliflozin: Terminal half-life ~12.9 hours (supports once-daily dosing). Saxagliptin: Terminal half-life ~2.5 hours, but active metabolite 5-hydroxy saxagliptin has half-life ~3.1 hours (supports once-daily dosing due to prolonged DPP-4 inhibition).
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
Dapagliflozin is primarily metabolized via glucuronidation by UGT1A9; saxagliptin is metabolized via CYP3A4/5 to an active metabolite.
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Dapagliflozin: ~75% renal excretion (21% unchanged, 50% as major metabolite 3-O-glucuronide), ~21% fecal. Saxagliptin: ~75% renal excretion (12% unchanged, 22% as major metabolite 5-hydroxy saxagliptin, 41% as other metabolites), ~22% fecal.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Dapagliflozin: ~91% bound primarily to albumin. Saxagliptin: Negligible (<10% bound).
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
Dapagliflozin: Vd ~118 L (1.5 L/kg based on 70 kg, indicating extensive extravascular distribution). Saxagliptin: Vd ~71 L (1.0 L/kg based on 70 kg, indicating distribution into tissues).
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
Dapagliflozin: Oral bioavailability ~78% (high, influenced by food). Saxagliptin: Oral bioavailability ~75% (high, not significantly affected by food).
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
e GFR ≥45 m L/min/1.73 m²: No dose adjustment. e GFR 30–44 m L/min/1.73 m²: Not recommended due to limited data for saxagliptin. e GFR <30 m L/min/1.73 m²: Contraindicated due to dapagliflozin; do not initiate, discontinue if e GFR falls below 30.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Not recommended for saxagliptin (limited data) and caution for dapagliflozin. Child-Pugh Class C: Contraindicated or not recommended.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
Not established. Safety and efficacy in pediatric patients (<18 years) have not been studied.
Not indicated for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment; monitor renal function (e.g., e GFR) and volume status due to age-related decrease in renal function and increased risk of hypotension, dehydration, and acute kidney injury.
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
There is no black box warning for this combination product.
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
Pancreatitis,Heart failure,Hypoglycemia when used with insulin or insulin secretagogues,Acute kidney injury,Genital mycotic infections,Urinary tract infections,Hypotension,Ketoacidosis,Necrotizing fasciitis of the perineum (Fournier’s gangrene),Arthralgia,Bullous pemphigoid
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
History of serious hypersensitivity reaction to dapagliflozin, saxagliptin, or any component,Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease,Diabetic ketoacidosis,Type 1 diabetes mellitus
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
No specific food restrictions; alcohol may increase hypoglycemia risk.
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
Dapagliflozin is contraindicated in the second and third trimesters due to risk of fetal renal toxicity. Saxagliptin has limited human data; animal studies show no major malformations but potential for delayed ossification at high doses. First trimester: Use only if clearly needed; no well-controlled human studies. Second and third trimesters: Dapagliflozin not recommended; avoid.
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
No data on excretion in human milk. Dapagliflozin is present in rat milk; saxagliptin is excreted in rat milk. M/P ratio unknown. Caution advised due to potential for adverse effects in nursing infant.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
No specific dose adjustments established for pregnancy. Dapagliflozin is not recommended in pregnancy; consider alternative therapy. Saxagliptin: dose adjustment not required based on pharmacokinetic changes; however, lack of data limits recommendation.
Not applicable; contraindicated in pregnancy.
Monitor renal function before initiation and periodically; contraindicated if e GFR <45 m L/min/1.73 m². Assess volume status due to diuretic effect. Watch for pancreatitis and hypersensitivity. Adjust insulin or sulfonylurea doses to reduce hypoglycemia risk. Discontinue if pancreatitis suspected. T1DM is not an indication.
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
Take once daily with or without food; swallow tablets whole.,Stay hydrated to prevent dehydration from increased urination.,Genital mycotic infections may occur; report any symptoms.,Severe joint pain possible; advise seeking medical attention.,Do not share insulin pens or needles.,Store medication at room temperature away from moisture and heat.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
"Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin levels leading to glucose-dependent insulin secretion, while Milnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may independently affect glucose homeostasis. Concurrent use could theoretically increase the risk of hypoglycemia due to additive effects on insulin secretion or glucose metabolism, although clinical data are limited. Patients should be monitored for signs of hypoglycemia, especially if also on other glucose-lowering agents."
"Tolazamide, a sulfonylurea, increases insulin secretion from pancreatic beta cells, while saxagliptin, a DPP-4 inhibitor, prolongs the action of incretin hormones (GLP-1 and GIP) to enhance glucose-dependent insulin release. When coadministered, the complementary mechanisms can lead to additive hypoglycemic effects, significantly increasing the risk of hypoglycemia, particularly in patients with renal impairment or those on irregular meal schedules."
"Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been reported to potentially reduce the systemic exposure of theophylline, a xanthine bronchodilator, likely through the induction of cytochrome P450 (CYP) 1A2, the primary enzyme responsible for theophylline metabolism. This interaction may lead to subtherapeutic theophylline concentrations, resulting in decreased bronchodilator efficacy and potential exacerbation of respiratory symptoms, particularly in patients with asthma or chronic obstructive pulmonary disease. The effect appears to be modest but may be clinically relevant in patients requiring stable theophylline levels."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE vs ACTIVELLA, answered by our medical review team.
DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE is a DPP-4 Inhibitor that works by Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal renal tubule, reducing plasma glucose independent of insulin secretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, increasing insulin release and decreasing glucagon secretion.. ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE and ACTIVELLA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE is: Oral: 1 tablet (dapagliflozin 5 mg / saxagliptin 5 mg) once daily, taken with or without food, in combination with metformin or other glucose-lowering agents.. The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE and ACTIVELLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE is classified as Category A/B. Dapagliflozin is contraindicated in the second and third trimesters due to risk of fetal renal toxicity. Saxagliptin has limited human data; animal studies show no major malformati. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.